Orellanine
PreclinicalSmall molecule
Orellanine is one of 12 small molecule programs targeting Carcinoma, Renal Cell. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Carcinoma, Renal Cell
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Lenvima
EisaiPhase 3
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Savolitinib
AstraZenecaPhase 3
Cabometyx
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPreclinical
Inlyta
PPrism Pharmaceuticals
Preclinical
MK-4830
Merck & Co.Preclinical
PF-08634404
PfizerPreclinical
Combination 2
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Carcinoma, Renal Cell1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Orellanine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- OOncorena AB